Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri Acquires 30,000 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri bought 30,000 shares of Cue Biopharma stock in a transaction on Monday, December 16th. The shares were purchased at an average cost of $1.03 per share, for a total transaction of $30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares in the company, valued at $169,515.34. The trade was a 22.29 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Cue Biopharma Stock Performance

CUE stock opened at $1.07 on Thursday. The firm has a market cap of $67.78 million, a P/E ratio of -1.19 and a beta of 1.66. The stock’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.05. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.05. Cue Biopharma, Inc. has a 12-month low of $0.45 and a 12-month high of $3.20.

Institutional Trading of Cue Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in shares of Cue Biopharma by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after purchasing an additional 16,371 shares during the period. GSA Capital Partners LLP boosted its position in Cue Biopharma by 5.1% during the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock valued at $221,000 after purchasing an additional 14,104 shares during the period. Sigma Planning Corp grew its stake in Cue Biopharma by 50.9% during the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after buying an additional 135,295 shares during the last quarter. Good Life Advisors LLC increased its position in Cue Biopharma by 23.1% in the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after buying an additional 75,000 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Cue Biopharma in the second quarter valued at $66,000. 35.04% of the stock is owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.